Name: Chirag Kakadiya

College: IIPM

Ranbaxy Laboratory
1. History of the Organization

Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company,

is an integrated, research based, international pharmaceutical company,
producing a wide range of quality, affordable generic medicines, trusted by
healthcare professionals and patients across geographies. Ranbaxy today has a
presence in 23 of the top 25 pharmaceutical markets of the world. The Company
has a global footprint in 46 countries, world-class manufacturing facilities in 7
countries and serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese
innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and
generic pharmaceutical powerhouse. The combined entity now ranks among the
top 20 pharmaceutical companies, globally. The transformational deal will place
Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its
global reach and in its capabilities in drug development and manufacturing.
2. Key person of the company

At the helm of the entire operations is the experience and able direction of the
people who make it all happen. Ranbaxy acknowledges their inspiring
stewardship and indefatigable work.

Dr. Tsutomu Une
Chairman
Non Executive &
Non Independent Director

Mr. Arun Sawhney
Managing Director
 Mr. Takashi Shoda
Non Executive &
Non Independent Director

3. Product of the company

Products

Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited
manufactures and markets generic pharmaceuticals, value added generic
pharmaceuticals, branded generics, active Pharmaceuticals (API) and
intermediates.

The Company remains focused on ascending the value chain in the marketing of
pharmaceutical substances and is determined to bring in increased revenues from
dosage forms sales. Ranbaxy's diverse product basket of over 5,000 SKUs available
in over 125 countries worldwide, encompasses a wide therapeutic mix covering a
majority of the chronic and acute segments. Healthcare trends project that the
chronic treatment segments will outpace the acute treatment segments, primarily
driven by a growing aging population and dominance of lifestyle diseases. Our
robust performance in Cardiovasculars, Central Nervous System, Respiratory,
Dermatology, Orthopedics, Nutritionals and Urology segments, clearly indicates
that the Company has strengthened its presence in the fast-growing chronic and
lifestyle disease segments.
Top 10 Products (2009)

• Valacyclovir

• Simvastatin

• Co-Amoxyclav

• Ciprofloxacin and Combinations

• Amoxycillin and Combinations

• Isotretinoin

• Ketorolac Tromethamine

• Loratadine and Combinations

• Ginseng+Vitamins

• Cephalexin

• Atorvastatin and Combinations

4. How the product was identified

All the products were identified as different types of medicines for the different
diseases. These are the all branches of the different types of medicines offered by
Ranbaxy cardiovascular disease, diabetes, oncology, respiratory system, central
nervous system, dermatology, analgesics, anti-infective, bones and joint,
gastrointestinal disorders.

5. Existing competitors (companies offering similar products)

The pharmaceutical industry is characterized by rapid advances in scientific

knowledge and ability to discover new drugs. The industry is therefore led by
large manufacturers and marketers of drugs investing heavily in research
&development, having clinical testing, marketing and distributing capabilities.
Some of the main competitors of Ranbaxy are:
• Sun Pharmaceuticals Industries - It is No. 1 in India in specialty therapy areas
like psychiatry, neurology, cardiology, gastroenterology, dialectology and
respiratory.[.It has brands in 30 markets worldwide and also has a generic
presence in the U.S. with Carazo Parma Labs, Sun Pharmaceutical Industries Inc

• Cipla - Cipla is a leader in the domestic retail pharmaceutical market. It also

exports raw materials, intermediates, prescription drugs, over-the-counter
products, and veterinary products to some 180 countries around the world.

• Glaxo smith Kline- It is one of the oldest pharma companies in India and with a
turnover of Rs. 1500 crore is one of the market leaders (market share) in India
with a share of 6.2 per cent its main portfolios consists of anti- invectives,
dermatological and pain management drugs

• Dr.Reddy’s Laboratories- It is a global pharmaceutical company with it's

headquarters in India and a presence in more than 100 countries. In India it the
biggest drug maker by sales.

Other competitors are Actavis, Sandoz International GmbH; Teva

pharmaceuticals, RPG Enterprises, , East India Pharmaceutical Works Ltd, Concept
Pharmaceuticals Ltd, Khandelwal Laboratories Ltd, Dabur India Ltd.
6. Financial Status of the company

Profit & Loss a/c

7. Balance sheet of the company
8. How does the company market the product?

Marketing Strategies is the department focused primarily on developing and

executing strategies for the promotion and distribution of branded, generic and
OTC products for Ranbaxy. One of the key tasks for the department is to identify
opportunities in different markets and distribution channels and pursue those to
developing and establish new relationships in the marketplace. Managed Care
and Internet marketing is couple of key areas that the department is looking to
introduce into it’s ever- expanding service offerings.

9. What is the strategy of the business organization?

Ranbaxy is focused on increasing the momentum in the generics business in its

key markets through organic and inorganic growth routes. The Company
continues to evaluate acquisition opportunities in India, emerging and developed
markets to strengthen its business and competitiveness. Growth is well spread
across geographies with focus on emerging markets. Ranbaxy has forayed into
new specialty therapeutic segments like Bio-similar, Oncology, Peptides and
Limuses. These new growth areas will add significant depth to the existing
product pipeline.